GB2238476A - Therapeutic aquatic animal and garlic products - Google Patents
Therapeutic aquatic animal and garlic products Download PDFInfo
- Publication number
- GB2238476A GB2238476A GB8924968A GB8924968A GB2238476A GB 2238476 A GB2238476 A GB 2238476A GB 8924968 A GB8924968 A GB 8924968A GB 8924968 A GB8924968 A GB 8924968A GB 2238476 A GB2238476 A GB 2238476A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compositions
- garlic
- oils
- therapeutic
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Products comprised from oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin are useful in lowering cholesterol and saturated fat levels in blood.
Description
COMPOSITIONS OF SOME THERAPEUTIC ADVANTAGE FROM FISH AND
OTHER AQUATIC ANIMALS COMBINED WITH GARLIC INCLUDING OR
EXCLUDING THE GARLIC ACTIVE PRINCIPLE ALLICIN
This invention relates to a novel composition of therapeutic significance prepared from oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin.
Garlic has been used for thousands of years both as a culinary flavouring and as a preventative medicine. It appears to have a unique cardiovascular prophylactic effect.
It can significantly reduce blood fats and cholesterol, and seems to have an antithrombotic effect similar to that of aspirin.
The therapeutic value of oils derived from fish and other aquatic animals has only recently been appreciated. The are rich in long chain polyunsaturated fatty acids of the Omega3 series. The two most important Omega-3 acids are Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA).
These have been shown to have a hypotriglyceridaemic action and to a lesser extent a hypocholesterolaemic effect. When these fatty acids are present in the cell membranes and are metabolised to other compounds, the net results include antithrombotic and anti-inflammatory effects. Beneficial effects of these polyunsaturated fatty acids has also been noted in arthritis, cancer, diabetes, heart related diseases including high blood pressure and coronary heart disease, kidney related disorders and psoriasis.
Previously, garlic and aquatic animal preparations have always been presented seperately. Although these previously know individual compositions have given some therapeutic satisfaction, products combining the two would compliment each other and offer increased therapeutic advantage with improved patient compliance and convenience of a two-in-one therapy in a single dose.
It is therefore the principle object of this invention to provide products having therapeutic significance prepared from oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle
Allicin. These products will be presented in hard or soft gelatin capsules and as a liquid for oral administration.
These combination products providing a convenient two-in-one dosage form would have combined desired therapeutic properties which would be more effective than the presently available seperately existing compositions.
Accordingly, the above object has been achieved by providing the two therapies in combinationtcomprising oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals with oils and/or extracts and/r powders derived from mature or immature garlic including or excluding the garlic active principle Allicin. The mixture is encapsulated in hard or soft gelatin capsules or in a liquidoral form with or without any additives, oils or derivatives from plant and animal sources e.g. Beta-sitosterol, a naturally occuring substance found in wheat germ knows for its anticholesterol properties.
It is believed that these combination preparations of oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals with oils and/or extracts and/or powders derived from mature or immature garlic including or excluding active principle Allicin has an added therapeutic advantage over previously known seperately existing compositions.
The following examples illustrate the invention and the advantages thereof. These examples are given by way of illustration only, and are not to be construed as limiting the invention either in scope or in spirit, as many modifications will be apparent from this disclosure to those skilled in the art.
Example i:- Garlic Oil & Cod Liver Oil in Hard or Soft Gelatin
Capsules
COMPONENT AMOUNT PER CAPSULE
Garlic Oil 0.2 mg
Cod Liver Oil or Fish Oil 999.8 mg
The mixture is blended and then encapsulated in hard or soft gelatin capsules.
Example 2:- Garlic Oil & Cod Liver Oil in Hard or Soft Gelatin
Capsules
COMPONENT AMOUNT PER CAPSULE
Garlic Oil i.O mg
Cod Liver Oil or Fish Oil 99.0 mg
The mixture is blended and then encapsulated in hard or soft gelatin capsules.
Example 3:- Salmon Oil and Garlic Oil
COMPONENT AMOUNT PER TEASPOON (5 gm)
Salmon Oil 4.995 gm
Garlic Oil 0.005 gm
The mixture is blended with or without malt extract and then bottled.
Example 4:- Marine Animal Oil and Garlic Powder in Hard or Soft
P Gelatin Capsules
COMPONENT AMOUNT PER CAPSULE
Marine Animal Oil 0.75 gm
Garlic Powder 0.25 gm
The mixture is blended and then encapsulated in hard or soft gelatin capsules.
Example 5:- Marine Oil, Garlic Oil & Beta-sitosterol
COMPONENT AMOUSTT PER CAPSULE
Marine Oil 500 mg
Garlic Oil 0.2 mg Beta-sitosterol 100 mg
The mixture is blended and then bottled.
Products comprised from oils and/or derivatives and/or preparations derived from fish and /or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin combined as disclosed herein will have physiological properties of therapeutic importance with respect to the treatment and/or prophylaxis of arthris, cancer, diabetes, heart related diseases including high blood pressure and coranory heart disease, kidney related disorders and psoriasis. Garlic and aquatic animal oil have a dual antithrombotic and anti-inflammatory effect. They lower blood cholesterol and fat levels which is physiologically important.
Claims (8)
- i. Compositions of therapeutic significance comprising of oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals with oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin.
- 2. Compositions as in Claim 1 in which Beta-sitosterol (a derivative from wheat embryo) may or may not be used.
- 3. Compositions as in Claim 1 wherein one or more plant based additives and their derivatives or oils may or may not be incorporated.
- 4. Compositions as in Claims 1,2 & 3 wherein the mixture is encapsulated in hard or soft gelatin capsules.
- 5. Compositions as in Claims 1,2 & 3 wherein the mixture is bottled as an oral liquid supplement with or without additives such as malt.
- 6. Compositions as in Claims 2,3 & 4 whereby the product may be used as a therapeutic food for the treatment and/or prophylaxis of arthritis, cancer, diabetes, heart related diseases-including high blood pressure and coronary heart disease, kidney related disorders and psoriasis.
- 7. Compositions as in Claims 2,3,4 & 5 whereby the product may be used as an antithrombotic and/or anti-inflammatory.
- 8. Compositions as in Claims 2,3,4 & 5 in which the product may be used to lower blood cholesterol and saturated fat levels.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8924968A GB2238476A (en) | 1989-11-04 | 1989-11-04 | Therapeutic aquatic animal and garlic products |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8924968A GB2238476A (en) | 1989-11-04 | 1989-11-04 | Therapeutic aquatic animal and garlic products |
Publications (2)
Publication Number | Publication Date |
---|---|
GB8924968D0 GB8924968D0 (en) | 1989-12-28 |
GB2238476A true GB2238476A (en) | 1991-06-05 |
Family
ID=10665777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8924968A Withdrawn GB2238476A (en) | 1989-11-04 | 1989-11-04 | Therapeutic aquatic animal and garlic products |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2238476A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2706307A1 (en) * | 1993-06-18 | 1994-12-23 | Pelletier Jacques | Formula for the treatment of AIDS |
FR2706771A1 (en) * | 1993-06-21 | 1994-12-30 | Pelletier Jacques | Formula for the treatment of certain cancers. |
GB2304046A (en) * | 1995-08-08 | 1997-03-12 | Kofi Abaka Jackson | Diabetes therapy |
WO1998031372A1 (en) * | 1997-01-16 | 1998-07-23 | Dr. Kief Lizenz Verwertungs Gesellschaft Mbh | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
JP2012508791A (en) * | 2008-11-14 | 2012-04-12 | フラムローゼ,ボミ,ピー. | Method for reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for the treatment of atherosclerosis |
CN112535680A (en) * | 2019-09-20 | 2021-03-23 | 新疆埃乐欣药业有限公司 | Use of garlic-derived material for treating and/or preventing psoriasis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117752776B (en) * | 2024-02-22 | 2024-05-03 | 广东海洋大学 | A pharmaceutical preparation and its application in preparing a medicine for treating stress injury of babylonia after transportation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0232501A1 (en) * | 1985-12-19 | 1987-08-19 | Chimicasa Gmbh | Pharmaceutical preparation for the treatment of lipid metabolism disorders (hyperlipoproteinemia) |
EP0273407A2 (en) * | 1986-12-30 | 1988-07-06 | Roshdy Dr. Ismail | Medicine for improving the specific properties of blood |
DE3700785A1 (en) * | 1987-01-13 | 1988-07-21 | Sca Lohnherstellungs Ag | Macerate, process for its preparation and its use as medicine |
-
1989
- 1989-11-04 GB GB8924968A patent/GB2238476A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0232501A1 (en) * | 1985-12-19 | 1987-08-19 | Chimicasa Gmbh | Pharmaceutical preparation for the treatment of lipid metabolism disorders (hyperlipoproteinemia) |
EP0273407A2 (en) * | 1986-12-30 | 1988-07-06 | Roshdy Dr. Ismail | Medicine for improving the specific properties of blood |
DE3700785A1 (en) * | 1987-01-13 | 1988-07-21 | Sca Lohnherstellungs Ag | Macerate, process for its preparation and its use as medicine |
Non-Patent Citations (1)
Title |
---|
Martindale, The Extra Pharmacopoeia, (27th Edition) page 56 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2706307A1 (en) * | 1993-06-18 | 1994-12-23 | Pelletier Jacques | Formula for the treatment of AIDS |
FR2706771A1 (en) * | 1993-06-21 | 1994-12-30 | Pelletier Jacques | Formula for the treatment of certain cancers. |
GB2304046A (en) * | 1995-08-08 | 1997-03-12 | Kofi Abaka Jackson | Diabetes therapy |
GB2304046B (en) * | 1995-08-08 | 1998-12-09 | Kofi Abaka Jackson | Diabetes therapy |
WO1998031372A1 (en) * | 1997-01-16 | 1998-07-23 | Dr. Kief Lizenz Verwertungs Gesellschaft Mbh | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
DE19701264A1 (en) * | 1997-01-16 | 1998-07-23 | Kief Lizenz Verwertungsgesells | Remedies containing betasitosterol and / or phytosterol / betasitosteric mixtures |
US6407085B1 (en) | 1997-01-16 | 2002-06-18 | Horst Kief | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
JP2012508791A (en) * | 2008-11-14 | 2012-04-12 | フラムローゼ,ボミ,ピー. | Method for reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for the treatment of atherosclerosis |
CN112535680A (en) * | 2019-09-20 | 2021-03-23 | 新疆埃乐欣药业有限公司 | Use of garlic-derived material for treating and/or preventing psoriasis |
Also Published As
Publication number | Publication date |
---|---|
GB8924968D0 (en) | 1989-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5562913A (en) | Formulation for use in smokers | |
AU725308B2 (en) | Anti-stress composition | |
KR0126286B1 (en) | Fatty acid composition | |
DE60123849T2 (en) | OIL / GREASE COMPOSITION | |
JP3512196B2 (en) | Food composition comprising a balance regulator for omega-6 and omega-3 unsaturated fatty acids | |
JPH06128154A (en) | Food composition | |
KR20030016306A (en) | Therapeutic combinations of fatty acids | |
JPS6296422A (en) | Manufacture of preventive or therapeutic composition for endometric proliferation and prevention or remedy therefor | |
GB2148713A (en) | Pharmaceutical composition and food product comprising higher fatty acids | |
JPH05201924A (en) | Fatty acid composition | |
DE3213744A1 (en) | PHARMACEUTICAL AGENT | |
KR20040095263A (en) | Body temperature elevating agents | |
JPH11286497A (en) | Acylated derivative of glycosyl-l-ascorbic acid | |
GB2238476A (en) | Therapeutic aquatic animal and garlic products | |
EP1090635B1 (en) | Use of ferulic acid for treating hypertension | |
JPH0717515B2 (en) | Composition for treating benign prostatic hypertrophy | |
JPH0458847A (en) | Obesity-resistant fat and oil and obesity-resistant food | |
US20100239660A1 (en) | Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions | |
JPH0825876B2 (en) | Comedone therapeutic agent composition | |
DE3739700A1 (en) | Formulations containing alpha -linolenic acid (18:3, omega 3) and/or derivatives thereof, and process for their preparation and use in nutrition and medicine | |
JP2018104372A (en) | Composition containing krill oil and fish oil and perilla oil | |
JPH0336493B2 (en) | ||
JP4234888B2 (en) | Antihypertensive agent | |
JPS6216415A (en) | Medicinal composition for treating syndrome before menses and therapy therefor | |
CN107372861B (en) | Composition and application thereof in preparation of product for improving hyperlipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |